A Phase 3 trial of up to 160 patients, built around a composite functional endpoint and an adaptive design, is now locked in for OMT-28 after OMEICOS cleared what is often the most underappreciated gate in rare disease development: a productive end-of-phase 2 meeting with the FDA. The agency’s feedback was specific enough that OMEICOS can skip any intermediate bridging study and move directly from its concluded Phase 2a PMD-OPTION data into a pivotal program, a compression of development risk that most rare disease sponsors cannot pull off.
The Phase 3 design reflects the FDA’s constructive guidance in concrete ways. The primary endpoint pairs the 12-Minute Walk Test with the 5x Sit-to-Stand Test, capturing both endurance and functional mobility in a single composite rather than relying on a single instrument that could miss the heterogeneity across MELAS, non-MELAS, and MIDD subtypes. Treatment runs 24 weeks at a 24 mg once-daily dose, with an option to extend to 104 weeks. Exploratory biomarkers include NAD+ and GSH ratios, which align with OMT-28’s claimed dual mechanism: biased modulation of S1PR1 signalling that activates the mitochondrial sirtuins SIRT1 and SIRT3, targeting both redox balance and mitochondrial restoration simultaneously. The adaptive design allows interim sample-size adjustments, a tool the FDA has increasingly supported under its 2023 rare disease guidance for severely debilitating conditions. OMT-28 has now been evaluated in more than 190 individuals, and the Phase 2a data underscored a safety profile clean enough to include cardiomyopathy patients, a subgroup explicitly excluded from several competing programs.
The unmet need here is real but not absolute. FDA-approved options exist for narrow PMD subtypes, including TK2 deficiency and Barth syndrome, but approved options for the broader MELAS and MIDD populations that OMT-28 targets remain limited. The competitive field is active: Abliva’s KL1333 is running a 180-patient randomized Phase 2 called FALCON in adult patients with mitochondrial DNA mutations, covering overlapping fatigue and myopathy endpoints. OMT-28’s once-daily oral formulation and its inclusion of cardiomyopathy patients are genuine differentiators, but differentiation on paper means nothing until the Phase 3 primary endpoint holds up against randomized controls.
The number to track from here is the 12MWT delta in the responding patient subgroup from PMD-OPTION. That figure, when OMEICOS discloses it fully, will determine whether the Phase 3 sample size of 160 carries enough statistical power to survive an adaptive interim, and whether the FDA’s enthusiasm at the EOP2 meeting translates into a viable approval path in a genuinely heterogeneous disease population.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
